Sodium Iodide [131I] Injection GE Healthcare 925 MBq/ ml Норвегия - норвежки - Statens legemiddelverk

sodium iodide [131i] injection ge healthcare 925 mbq/ ml

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 925 mbq/ ml

Sodium Iodide [131I] Injection GE Healthcare 74 MBq/ ml Норвегия - норвежки - Statens legemiddelverk

sodium iodide [131i] injection ge healthcare 74 mbq/ ml

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 74 mbq/ ml

Theracap 131TM - Норвегия - норвежки - Statens legemiddelverk

theracap 131tm -

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard

Xylocain 2 % Норвегия - норвежки - Statens legemiddelverk

xylocain 2 %

aspen pharma trading limited - lidokainhydrokloridmonohydrat - gel - 2 %

Kigabeq Европейски съюз - норвежки - EMA (European Medicines Agency)

kigabeq

orphelia pharma sas - vigabatrin - spasms, infantile; epilepsies, partial - antiepileptics, - kigabeq er angitt i spedbarn og barn fra 1 måned til mindre enn 7 års alder for:behandling i monoterapi av infantile spasmer (vest-syndrom). behandling i kombinasjon med andre antiepileptiske legemidler for pasienter med resistente partiell epilepsi (focal utbruddet beslag) med eller uten sekundær generalisering, som er der hvor alle andre aktuelle legemiddelet kombinasjoner har vist seg å være utilstrekkelige eller ikke er tolerert.

Xylocain 2 % Норвегия - норвежки - Statens legemiddelverk

xylocain 2 %

2care4 aps - lidokainhydrokloridmonohydrat - gel - 2 %

Lonquex Европейски съюз - норвежки - EMA (European Medicines Agency)

lonquex

teva b.v. - lipegfilgrastim - nøytropeni - immunostimulants, , koloni stimulerende faktorer - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Mircera Европейски съюз - норвежки - EMA (European Medicines Agency)

mircera

roche registration gmbh - metoksy polyetylen glykol-epoetin beta - anemia; kidney failure, chronic - antianemiske preparater - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.